Monthly Archives: March 2017

Replicel’s cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon – Seeking Alpha

Posted: March 29, 2017 at 2:44 am

Results from an eight-subject Phase 1/2 clinical trial, ReaCT, assessing a single injection of Replicel Life Sciences' (OTCQB:REPCF) RCT-01 into the Achilles tendon of patients with Achilles tendinosis showed clinically important improvements including pain sensation, physical function, blood supply and tendon composition.

Achilles tendinosis is a degenerative process of the tendon that does to present with signs like inflammation either clinically or by examining tissue samples under a microscope, but is associated with pain and loss of function. There are no effective therapies for the condition.

Participants showed clinically relevant signs of healing six months after injection as measured by an overall 15.3% improvement in a scale called VISA-A. Two patients achieved almost total recovery. Four of five patients who completed questionnaires showed relevant signs of improvement in pain on loading (running/jumping) based on a scale called VAS. The average improvement in VAS score from baseline was 62.9%. Three of the five patients experienced improvements in pain on palpation (feeling the tendon with the hands during a physical exam). The average improvement in VAS score from baseline was 55.2%.

All study participants except one experienced at least one adverse event, either injection site soreness or observation of a partial thickness tear in the tendon after the injection.

RCT-01 is an autologous cell therapy that uses non-bulbar dermal sheath cells isolated from the hair follicle sheath. Developmentis ongoing.

Here is the original post:
Replicel's cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon - Seeking Alpha

Posted in Cell Therapy | Comments Off on Replicel’s cell therapy candidate RCT-01 shows treatment effect in patients with degenerated Achilles tendon – Seeking Alpha

Have you checked yourself for diabetes? – Radio Iowa

Posted: March 29, 2017 at 2:43 am

This is Diabetes Alert Day and Iowans are being urged to take a simple, on-line survey to determine if they might be headed down a hazardous path.

Katie Jones, program manager at the Iowa Department of Public Health, says it only takes a minute to complete the test. Jones says, This is really to see if youre at risk for a condition called prediabetes which is basically where blood glucose levels or blood sugar levels are higher than normal but not high enough yet to be considered diabetes.

The website is: DoIHavePrediabetes.org. Jones says about one in every three Iowans is prediabetic and most of them dont know it.

The test asks things like your age, because age is a big risk factor, Jones says. Simply getting older increases your risk. It also asks things like family history of diabetes, things like that. About one in 12 Iowans has diabetes and one in four has it and doesnt know it. By knowing your risk level, Jones says Iowans can make a few key lifestyle changes to stave off type 2 diabetes.

The good news is, if you do have prediabetes, you can take steps to help prevent developing type 2 diabetes and even getting rid of prediabetes, Jones says. The National Diabetes Prevention Program can help you actually curb that progression.

People with type 2 diabetes are at higher risk for heart disease, stroke and other serious complications. Prediabetes can often be reversed through modest weight loss 5 to 7 percent of body weight and making small changes to increase healthy eating and moderate physical activity.

Go here to read the rest:
Have you checked yourself for diabetes? - Radio Iowa

Posted in Diabetes | Comments Off on Have you checked yourself for diabetes? – Radio Iowa

MIT Mathematician Develops an Algorithm to Help Treat Diabetes – Smithsonian

Posted: March 29, 2017 at 2:43 am

Tools of diabetes treatment almost always include improved diet and regular exercise.

When people ask me why I, an applied mathematician, study diabetes, I tell them that I am motivated for both scientific and human reasons.

Type 2 diabetes runs in my family. My grandfather died of complications related to the condition. My mother was diagnosed with the disease when I was 10 years old, and my Aunt Zacharoula suffered from it. I myself am pre-diabetic.

As a teen, I remember being struck by the fact that my mother and her sister received different treatments from their respective doctors. My mother never took insulin, a hormone that regulates blood sugar levels; instead, she ate a limited diet and took other oral drugs. Aunt Zacharoula, on the other hand, took several injections of insulin each day.

Though they had the same heritage, the same parental DNA and the same disease, their medical trajectories diverged. My mother died in 2009 at the age of 75 and my aunt died the same year at the age of 78, but over the course of her life dealt with many more serious side effects.

When they were diagnosed back in the 1970s, there were no data to show which medicine was most effective for a specific patient population.

Today,29 million Americansare living with diabetes. And now, in an emerging era of precision medicine, things are different.

Increased access to troves of genomic information and the rising use of electronic medical records, combined with new methods of machine learning, allow researchers to process large amounts data. This is accelerating efforts to understand genetic differences within diseases including diabetes and to develop treatments for them. The scientist in me feels a powerful desire to take part.

My students and I have developed adata-driven algorithm for personalized diabetes management that we believe has the potential to improve the health of the millions of Americans living with the illness.

It works like this: The algorithm mines patient and drug data, finds what is most relevant to a particular patient based on his or her medical history and then makes a recommendation on whether another treatment or medicine would be more effective. Human expertise provides a critical third piece of the puzzle.

After all, it is the doctors who have the education, skills and relationships with patients who make informed judgments about potential courses of treatment.

We conducted our research through a partnership with Boston Medical Center, the largest safety net hospital in New England that provides care for people of lower income and uninsured people. And we used a data set that involved the electronic medical records from 1999 to 2014 of about 11,000 patients who were anonymous to us.

These patients had three or more glucose level tests on record, a prescription for at least one blood glucose regulation drug, and no recorded diagnosis of type 1 diabetes, whichusually begins in childhood. We also had access to each patients demographic data, as well their height, weight, body mass index, and prescription drug history.

Next, we developed an algorithm to mark precisely when each line of therapy ended and the next one began, according to when the combination of drugs prescribed to the patients changed in the electronic medical record data. All told, the algorithm considered 13 possible drug regimens.

For each patient, the algorithm processed the menu of available treatment options. This included the patients current treatment, as well as the treatment of his or her 30 nearest neighbors in terms of the similarity of their demographic and medical history to predict potential effects of each drug regimen. The algorithm assumed the patient would inherit the average outcome of his or her nearest neighbors.

If the algorithm spotted substantial potential for improvement, it offered a change in treatment; if not, the algorithm suggested the patient remain on his or her existing regimen. In two-thirds of the patient sample, the algorithm did not propose a change.

The patients who did receive new treatments as a result of the algorithm sawdramatic results. When the systems suggestion was different from the standard of care, anaverage beneficial changein the hemoglobin of 0.44 percent at each doctors visit was observed, compared to historical data. This is a meaningful, medically material improvement.

Based on the success of our study, we are organizing a clinical trial with Massachusetts General Hospital. We believe our algorithm could be applicable to other diseases, including cancer, Alzheimers, and cardiovascular disease.

It is professionally satisfying and personally gratifying to work on a breakthrough project like this one. By reading a persons medical history, we are able to tailor specific treatments to specific patients and provide them with more effective therapeutic and preventive strategies. Our goal is to give everyone the greatest possible opportunity for a healthier life.

Best of all, I know my mom would be proud.

Dimitris Bertsimas, Professor of Applied Mathematics, MIT Sloan School of Management

Like this article? SIGN UP for our newsletter

Original post:
MIT Mathematician Develops an Algorithm to Help Treat Diabetes - Smithsonian

Posted in Diabetes | Comments Off on MIT Mathematician Develops an Algorithm to Help Treat Diabetes – Smithsonian

Groups gather to fight diabetes – The Salinas Californian

Posted: March 29, 2017 at 2:43 am

Jeff Mitchell, Community Health Reporting Project Published 4:27 p.m. PT March 28, 2017 | Updated 6 hours ago

community health reporting project logo(Photo: Provided)

Realizing that the Salinas Valley, like much of America, is about to get hit with a tsunami of pre-diabetes and diabetes cases, a handful of local healthcare organizations joined Tuesday to fight the chronic disease that shortens lives and regularly robs people of limbs through amputation and dims or extinguishes their eyesight.

The countywide initiative is a partnership among Salinas Valley Memorial Healthcare System, Community Health Innovations, Montage Health, Monterey Independent Physicians Association and Central Coast YMCA.

The announcement was made at the Salinas Valley Medical Clinic Diabetes & Endocrine Center currently under construction at the Primecare Medical offices on Abbott Street.

The Diabetes Initiative was started in 2015 by Community Hospital, SVMH, Community Health Innovations (CHI) and the Monterey Bay Independent Physician Association to move the dial on diabetes.

The driver behind todays event is the bold effort by the partners to work together to move the dial on diabetes in Monterey County," said Dr. Anthony Chavis, chief medical officer of Montage Health, parent company of Community Hospital of the Monterey Peninsula.

The effort comes not a minute too soon. According to the UCLA Center for Health Policy Research Chronic Disease Program, diabetes and pre-diabetes in Monterey County affect:

57% of the population has diabetes and pre-diabetes

28,000, or 12% of the population, have diabetes

105,000, or 45% of the population, have pre-diabetes.

In 2015, about 13.8% of Monterey County Hispanics/Latinos reported having been diagnosed with diabetes, compared to 4.8% of Whites and 4.4% Asians (CHIS).

The partners supporting the initiative have increased the number of endocrinologists serving the community. The YMCA introduced a yearlong Pre-Diabetes Program for people considered pre-diabetes or are on the verge of becoming pre-diabetic.

This year, SVMHS is opening an expanded Diabetes & Endocrine Center in Salinas with a state-of-the-art kitchen and education room. Also this year, Montage Health is opening a new medical office building at Ryan Ranch ideally suited for diabetes care.

Construction of the expanded Salinas Valley Medical Clinic Diabetes & Endocrine Center will be completed this summer. The new Diabetes & Endocrine Center will be located on the second floor of the PrimeCare office building at 355 Abbott St.in Salinas.

Read or Share this story: http://bit.ly/2nK6LJU

Read more from the original source:
Groups gather to fight diabetes - The Salinas Californian

Posted in Diabetes | Comments Off on Groups gather to fight diabetes – The Salinas Californian

Signs of Diabetes: Look to the Feet – PA home page

Posted: March 29, 2017 at 2:43 am

SCRANTON, LACKAWANNA COUNTY (WBRE/WYOU) Today, Tuesday, March 28, 2017, is American Diabetes Association Alert Day. The goal is to bring awareness about a disease that affects tens of millions of Americans.

While 29 million Americans are dealing with diabetes, another 86 million have prediabetes yet only a fraction are aware of it. A doctor and a diabetic patient spoke about a part of the body that's often the first to signal you may be at risk of having the disease.

42-year-old DavidWanchisen visited his foot doctor Tuesday morning. The Scranton man didn't expect he'd end up here but it's the result of a diagnosis last year that took him by surprise. "I'm dealing with a diabetic ulcer that it's curing but it takes a lot of time and a little bit of pain."

He's wearing an orthowedge shoe to reduce pressure on that diabetic ulcer. Before he had the wound, the first physical sign he had Type 2 diabetes surfaced after a summer day at the beach. "Neuropathy on my feet caused the burning." That burning pain, weakness and numbness were a result of his diabetic condition. "I might have had it for quite some time."

Commonwealth Health Podiatrist Laura Virtue-Delayo, DPM said, "Oftentimes it's that they're getting tingling in their toes or burning." She added that many patients first learn of their diabetes by having a sore on their foot that's not getting better. "When you have a wound, the longer it's open the better chance of getting an infection in the soft tissue, in the bone, which can lead to amputation of the toes, the forefoot or even the lower leg."

Dave's treatment includes having the doctor debride, or scrape, his wound once a week while he has to apply a specialized ointment to that area every day. He's also eating healthier and lost 50 pounds in less than a year. "You have to make a lifestyle change to somewhat cure it or you know improve your lifestyle." Dr. Virtue-Delayo added, "He definitely is working on keeping his sugars in tact so they don't have to be a problem. You can be a diabetic without having foot problems or other problems that go along with diabetes."

Dr. Virtue-Delayo says a diabetic who notices a foot wound, even a blister, should call the doctor as soon as possible. She says delaying treatment even a few days could lead to amputation.

Link:
Signs of Diabetes: Look to the Feet - PA home page

Posted in Diabetes | Comments Off on Signs of Diabetes: Look to the Feet – PA home page

Crestwood Medical Center stresses the prevalence of diabetes in Alabama – whnt.com

Posted: March 29, 2017 at 2:43 am

Crestwood Medical Center is owned by CHS.

Crestwood Medical Center is owned by CHS.

HUNTSVILLE, Ala. March 28represents Diabetes Alert Day, sponsored by the American Diabetes Association. Its a disease that affects millions of people in the United States.

In an effort to remind Americans about the seriousness and prevalence of this disease, Crestwood Medical Center is taking action against it.

Diabetes is a part of life for 30-million people in the United States.

Actually in Alabama, were a little bit higherwere actually one in seven people in Alabama has diabetes, said registered nurse and diabetes educator, Cynthia Roberts. Unfortunately, about one in four people are walking around un-diagnosed.

Roberts saidthere are a few questions you need to ask yourself regarding diabetes.

Do you have a family member that has diabetes? Are you overweight? If youre over the age of 45 that puts you at risk.

Roberts said there are steps you can take to delay the onset of diabetes or prevent it all together.

Being more physically active, said Roberts. The recommendation is 150 minutes of intentional physical activity per week. Thats just like 30 minutes of walking, 5 times a week.

The second thing to keep in mind is your diet. Roberts said dont cut one food group out all together, instead try to make your meals more balanced.

Original post:
Crestwood Medical Center stresses the prevalence of diabetes in Alabama - whnt.com

Posted in Diabetes | Comments Off on Crestwood Medical Center stresses the prevalence of diabetes in Alabama – whnt.com

Diabetes mellitus testing has changed over the years – Rapid City Journal

Posted: March 29, 2017 at 2:43 am

Testing for diabetes started a long, long time ago. The word diabetes comes from ancient Greek and literally means pass through," intended to mean excessive passing of urine.

This characteristic of too much urine was first described 3500 years ago on an Egyptian papyrus. About 1900 years ago, Roman physician Galen called it diarrhea of the urine. The reason for so much passing of urine with diabetes mellitus is because high levels of sugar in the blood overwhelm the kidneys' ability to keep sugar out of the urine. Like a dam on a river, sugar spills over the dam into the urine when sugar gets too high in the blood. Then, with concentrated sugar in the urine, fluid is pulled out of blood into the urine, resulting in dehydration of the diabetic. Indeed, the name diarrhea of the urine seems appropriate.

About 2500 years ago, someone noted flies were attracted to the urine of diabetics. Tasting urine for sweetness may seem disgusting today, but it was how they diagnosed diabetes all the way through the Middle Ages. It was English physician John Rolle who in the 1700's added mellitus to the term diabetes to reflect the age-old understanding of the sweet taste of the urine in diabetic patients. The word mellitus comes from Latin meaning sweetened with honey.

Starting in the 1950's, patients roughly estimated the level of sugar in their blood by testing their urine with a chemical test they could do at home. By determining how much sugar spilled into the urine, people with diabetes mellitus were better able to adjust their insulin dose. Home URINE glucose testing was an improvement for patients with diabetes, but home BLOOD glucose testing, developed in the '80's, took it to the next level. Patients could finally know when sugars were too low, not just too high.

Another great improvement in monitoring the blood sugar of diabetics was the development of the Hemoglobin A1c (HbA1c) BLOOD test. The hemoglobin molecule within red blood cells becomes more sugarized (the scientific word is glycosylated) when it has extended exposure to higher levels of sugar. Since red cells normally live for about three-months, we can monitor the percentage of Hemoglobin affected by sugar, watching it change slowly according to diabetic control. The HbA1c levels give a three-month average BLOOD sugar, which gives you and your care provider a good measure about how well you are controlling your diabetes over time.

It's a good thing managing diabetes no longer requires tasting urine.

Continued here:
Diabetes mellitus testing has changed over the years - Rapid City Journal

Posted in Diabetes | Comments Off on Diabetes mellitus testing has changed over the years – Rapid City Journal

Why Cellect Biotechnology Stock Is Skyrocketing Today – Motley Fool

Posted: March 28, 2017 at 4:42 am

What happened

Cellect Biotechnology (NASDAQ:APOP), an Israeli-based stem-cell company, today announced the first successful stem cell transplant procedure using its ApoGraft technology in a combined phase 1/2 clinical trial in a blood cancer patient, causing its shares to rise by as much as 115%. The company's stock has since cooled off, but is still up by 80% as of 3:00 p.m. EDT.

Image source: Getty Images.

Even though stem cell transplants can be a curative treatment for many blood disorders and blood-related cancers, they tend to be a treatment of last resort because of their life-threatening side effects, such as graft-versus-host disease (GvHD). So, if Cellect's ApoGraft technology turns out to be a viable workaround, it would be a major advancement in the field, and potentially an extremely lucrative product for the company.

While Cellect's announcement is indeed exciting, its stock still isn't a great long-term bet. Cellect exited 2016 with a paltry $8 million in cash andApoGraft is probably five to six years away from reaching the market. This current trial, after all, is simply a safety and proof-of-concept study that's not designed to provide a basis for a regulatory approval.

In addition, Bellicum Pharmaceuticals'adjunct T-cell therapy BPX-501 could reach the European market as one possible solution to the GvHD problem in blood cancer patients by early 2019, and in the U.S. by perhaps 2020. In other words, Bellicum has a significant head start on Cellect, which may diminish the commercial prospects ofApoGraft moving forward.

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Continued here:
Why Cellect Biotechnology Stock Is Skyrocketing Today - Motley Fool

Posted in Biotechnology | Comments Off on Why Cellect Biotechnology Stock Is Skyrocketing Today – Motley Fool

Biotechnology Gets A Shot In the Arm – Barron’s

Posted: March 28, 2017 at 4:42 am

Biotechnology Gets A Shot In the Arm
Barron's
The healthcare sector has been doing rather well, gaining 8.9% year-to-date. Behind just information technology, healthcare stocks have outpaced Trump sectors including materials, industrials, and financials so far, suggesting that investors may be ...
iShares Nasdaq Biotechnology (IBB) volatility low into Credit Suisse ...StreetInsider.com
iShares NASDAQ Biotechnology Index (IBB) Rating Increased to ...BBNS

all 5 news articles »

Go here to see the original:
Biotechnology Gets A Shot In the Arm - Barron's

Posted in Biotechnology | Comments Off on Biotechnology Gets A Shot In the Arm – Barron’s

First successful stem cell cancer transplant sees Cellect Biotechnology shares surge – Proactive Investors USA & Canada

Posted: March 28, 2017 at 4:42 am

Cellect Biotechnology Ltd (NASDAQ:APOP, TASE:APOP) shares shot up 74% in New York after it successfully performed the first stem cell transplant procedure on a cancer patient.

It happened in the group's phase I/II clinical trial in a blood cancer patient.

The stem cell firm's chief executive Dr Shai Yarkoni said: After 15 years of research, this is the first time we have used our technology on a cancer patient suffering from life-threatening conditions.

"It is a first good step on a road that we hope will lead to stem cell based regenerative medicine becoming a safe commodity treatment at every hospital in the world.

Up to half of all stem cell transplant procedures, such as bone marrow transplants, result in life-threatening rejection disease, known as Graft-versus-Host-Disease (GvHD).

But the firm's ApoGraft technology aims to stop all that.

Now, the independent data and safety monitoring board (DSMB) has approved the enrolment of two further patients for the ApoGraft treatment to complete the first study cohort as planned.

Shares shot up 74% to reach $10.9 each.

Register here to be notified of future PROAC Company articles

Visit link:
First successful stem cell cancer transplant sees Cellect Biotechnology shares surge - Proactive Investors USA & Canada

Posted in Biotechnology | Comments Off on First successful stem cell cancer transplant sees Cellect Biotechnology shares surge – Proactive Investors USA & Canada